Ark Therapeutics highlights progress in business development

Ark Therapeutics' latest interim management statement has underlined the progress the company is making towards becoming a leading contract development and manufacturing business.

During the period from July 1st 2012 to the current date (November 8th 2012), the organisation has achieved a number of milestones, including the agreement of a manufacturing partnership with a leading European gene therapy firm and new collaborations with Merck Millipore and Laurantis Pharma Oy.

The firm has also maintained its successful partnership with PsiOxus Therapeutics and achieved cost savings through a number of efficiency measures.

Moreover, Dr David Venables has been installed as chief executive officer of Ark, following the departure of Martyn Williams at the end of July.

Dr Venables said: "I am deeply encouraged by the progress we have made since the company transitioned to a services-orientated revenue-generating business earlier this year."

Ark Therapeutics' business activities focus on the important fields of vascular disease and cancer, two of the largest therapeutic markets in the world.